Literature DB >> 23434923

Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state.

Marcel Arndt1, Hitesh Chokshi, Kin Tang, Neil J Parrott, Christos Reppas, Jennifer B Dressman.   

Abstract

Human biorelevant media have been shown to be a useful tool in pharmaceutical development and to provide input for in silico prediction of pharmacokinetic profiles after oral dosing. Dogs, in particular Beagles, are often used as animal models for preclinical studies. Key differences in the composition of human and canine gastric and intestinal fluids are described in the literature and underscore the need to develop a discrete set of biorelevant media, adapted to the conditions of the proximal canine gastrointestinal (GI) tract, to improve forecast and interpretation of preclinical results using in vitro dissolution studies. Canine biorelevant media can also be used in the development of oral dosage forms for companion animals, which is a rapidly growing market. The compositions of Fasted State Simulated Gastric Fluid canine (FaSSGFc) and Fasted State Simulated Intestinal Fluid canine (FaSSIFc) are adapted to the physiological composition of the corresponding gastrointestinal fluids in terms of pH, buffer capacity, osmolality, surface tension, as well as the bile salt, phospholipid, and free fatty acid content (in terms of concentration and reported subtypes). It was demonstrated that canine Fasted State Simulated Intestinal Fluid (FaSSIFc) is superior in predicting the solubility of model compounds in Canine Intestinal Fluid (CIF) compared to the human biorelevant media (FaSSIF and FaSSIF-V2). Two different versions of FaSSGFc, composed at pH 1.5 and pH 6.5, offer the possibility to design in vitro studies which correspond to the in vivo study design, depending on whether pentagastrin is used to decrease the gastric pH in the dogs or not. Canine biorelevant media can therefore be recommended to achieve more accurate forecasting and interpretation of pharmacokinetic studies of oral drug products in dogs.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23434923     DOI: 10.1016/j.ejpb.2013.01.010

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and Dissolution in Dogs.

Authors:  M N Martinez; B Mistry; V Lukacova; K A Lentz; J E Polli; S W Hoag; T Dowling; R Kona; R M Fahmy
Journal:  AAPS J       Date:  2017-03-06       Impact factor: 4.009

Review 2.  Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics.

Authors:  Marilyn N Martinez; Jonathan P Mochel; Sibylle Neuhoff; Devendra Pade
Journal:  AAPS J       Date:  2021-04-27       Impact factor: 4.009

3.  pH-Dependent Solubility and Dissolution Behavior of Carvedilol--Case Example of a Weakly Basic BCS Class II Drug.

Authors:  Rania Hamed; Areeg Awadallah; Suhair Sunoqrot; Ola Tarawneh; Sami Nazzal; Tamadur AlBaraghthi; Jihan Al Sayyad; Aiman Abbas
Journal:  AAPS PharmSciTech       Date:  2015-07-23       Impact factor: 3.246

4.  In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets.

Authors:  Deanna M Mudie; Aaron M Stewart; Jesus A Rosales; Molly S Adam; Michael M Morgen; David T Vodak
Journal:  Pharmaceutics       Date:  2021-08-13       Impact factor: 6.321

5.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

6.  Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine.

Authors:  Aki T Heikkinen; Arno Friedlein; Mariette Matondo; Oliver J D Hatley; Aleksanteri Petsalo; Risto Juvonen; Aleksandra Galetin; Amin Rostami-Hodjegan; Ruedi Aebersold; Jens Lamerz; Tom Dunkley; Paul Cutler; Neil Parrott
Journal:  Pharm Res       Date:  2014-07-18       Impact factor: 4.200

7.  Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.

Authors:  Yu Fang; Guozheng Wang; Rong Zhang; Zhihua Liu; Zhenghua Liu; Xiaohui Wu; Deying Cao
Journal:  AAPS PharmSciTech       Date:  2014-03-05       Impact factor: 3.246

8.  Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs.

Authors:  Deanna M Mudie; Aaron M Stewart; Jesus A Rosales; Nishant Biswas; Molly S Adam; Adam Smith; Christopher D Craig; Michael M Morgen; David T Vodak
Journal:  Pharmaceutics       Date:  2021-04-15       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.